Highlights Newsletter 1

This newsletter presents you the following key sessions:

• Watch the video interview with dr. Robert M. Jotte about the results of the phase III IMpower 131 trial: addition of atezolizumab to chemotherapy as first-line therapy for patients with advanced squamous NSCLC results in doubling of the PFS

• Shorter trastuzumab treatment as effective for HER2-positive breast cancer, with less cardiac toxicity

• Lynch syndrome is common among cancer patients with tumours with high microsatellite instability

• Matching treatment to specific genetic changes improves survival across multiple tumor types

• Modest delay in disease progression with the PIK3CA inhibitor taselisib in women with advanced breast cancer